|
Daniel Odenheimer joined the HGS drug development team in 1998. In 2003 he was promoted to Vice President Clinical Research - General Medicine. Dr. Odenheimer's responsibilities include developing clinical plans for new products designing clinical trials and recruiting and monitoring clinical trial investigators for clinical trials. Prior to joining HGS Dr. Odenheimer worked at British Biotech Inc. where he was Director U.S. Clinical Research. Among his responsibilities were directing the U.S. clinical development of marimastat in lung cancer and non-oncology indications. Previously Dr. Odenheimer worked at Boehringer Mannheim Corporation's Therapeutics division. During his eight years there he advanced through a series of positions including Director Department of Clinical Research. Dr. Odenheimer earned a Ph.D. in Epidemiology and an M.S. degree in Biostatistics at the University of Michigan. He earned an M.S. in Epidemiology and a B.S. in Genetics from the University of California Berkeley. | 